Three doses of vaccine from the COVID-19 Chinese company SINOVAC – the two first components and boosters – do not cause a sufficient immune response to the Coronavirus option “Oomikron”, reports Bloomberg with reference to a laboratory study.
According to the results of the study of the University of Hong Kong and the University of Hong Kong, people who have passed the initial vaccination with SINOVAC drug should be considered as a booster vaccine of other companies. At the same time, researchers advise the third dose of Pfizer / Biontech vaccine, since it significantly increases the level of antibodies to “Oomikron” at the grafted Chinese vaccine.
In addition, according to the results of the study, it is said that at the same time, two doses of Pfizer / Biontech vaccine are not effective in protecting on the Oomikron version, but together with the booster this drug significantly increases the level of protection against this strain.
Bloomberg notes that Omicron extends about 70 times faster than its predecessor of the Delta strain. The agency recalls that last week in Sinovac company stated: three doses of their vaccine cause the production of antibodies in 94% of cases. At the same time, the company did not specify how high the level of antibodies cause vaccination with the drug.